ACTU Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Actuate Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerACTU

Market Cap48.8M

Cash RunwayRunway < 6 months

Next Catalyst2026-12-31

Public Research Snapshot

Actuate Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for 9-ING-41 in Pancreatic Adenocarcinoma (Phase 2) using Small Molecule.

Pipeline

Asset	Indication	Modality	Stage	Public Note
GSK-3	cancers	Small Molecule	n/a	Public pipeline row
9-ING-41	Pancreatic Adenocarcinoma	Small Molecule	Phase 2	Public pipeline row
Gemcitabine	n/a	n/a	Phase 2	Public pipeline row
Ruxolitinib	Myelofibrosis	n/a	Phase 2	Public pipeline row
FOLFIRNINOX	Pancreatic Adenocarcinoma \| Pancreatic Adenocarcinoma Metastatic	n/a	Phase 2	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2026-12-31	FOLFIRNINOX	Low
		Clinical Trial Completion	2033-06-18	9-ING-41	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT04218071	Phase 2	COMPLETED	17	2022-10-13
NCT05239182	Phase 2	TERMINATED	7	2022-12-20
NCT05010629	Phase 2	ACTIVE_NOT_RECRUITING	35	2025-02-14
NCT04239092	Phase 1	TERMINATED	40	2025-07-07
NCT05116800	Phase 2	WITHDRAWN	n/a	2025-08-01
NCT03678883	Phase 2	ACTIVE_NOT_RECRUITING	350	2026-06
NCT05077800	Phase 2	ACTIVE_NOT_RECRUITING	70	2026-12-31
NCT04832438	Phase 2	WITHDRAWN	n/a	2033-06-18

Scientific Context

literature_publication | uPAR deficiency triggers TGFβ1-mediated fibrotic remodeling in a cardiac perivascular-like microenvironment.
literature_publication | Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma.
literature_publication | Implementation of an Educational Intervention for Gastric Cancer Awareness in the General Population in CELAC and Europe: A Strategy Proposed by the LEGACy Consortium.
literature_publication | Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.
literature_publication | Glycogen synthase kinase 3 activity enhances liver inflammation in MASH.

Want the full ACTU research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.